Published Online:August 03, 2015https://doi.org/10.3928/00485713-20150803-06
Abstract
For a woman with bipolar disorder, decompensation during the course of pregnancy can have significant consequences for both her and the baby. Women with bipolar disorder are also at greater risk for unplanned pregnancy. Therefore, it is essential that psychiatric providers proactively discuss pregnancy plans and treatment options during pregnancy and lactation with all women of reproductive age. Mood stabilizing medications and nonpharmacologic treatment options are equally important components of treatment for bipolar disorder. A comprehensive treatment plan should include a thoughtful discussion about the risks of untreated illness, balanced alongside with the risks and benefits of treatment. [Psychiatr Ann. 2015;45(8):411–416.]
- 1.Freeman MP, Smith KW, Freeman SA, The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002; 63(4):284–287.
10.4088/JCP.v63n0403 CrossrefGoogle Scholar - 2.Viguera AC, Whitfield T, Baldessarini R, Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007; 164(12):1817–1824.
10.1176/appi.ajp.2007.06101639 CrossrefGoogle Scholar - 3.Yonkers K, Vigod S, Ross L. Diagnosis, pathophysiology and management of mood disorders in pregnant and postpartum women. Obstetrics Gynecol. 2012; 117(4):961–977.
10.1097/AOG.0b013e31821187a7 CrossrefGoogle Scholar - 4.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington, VA: American Psychiatric Association; 2013. Google Scholar
- 5.Sharma V, Mazmanian D. The DSM-5 peripartum specifier: prospects and pitfalls. Arch Womens Ment Health. 2014; 17:171–173.
10.1007/s00737-013-0406-3 CrossrefGoogle Scholar - 6.Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of Recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry2000; 157(2):179–184.
10.1176/appi.ajp.157.2.179 CrossrefGoogle Scholar - 7.Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345:e7085.
10.1136/bmj.e7085 CrossrefGoogle Scholar - 8.Heron J, McGuinness M, Robertson Blackmore E, Craddock N, Jones I. Early postpartum symptoms in puerperal psychosis. BJOG. 2008; 115:348–353.
10.1111/j.1471-0528.2007.01563.x CrossrefGoogle Scholar - 9.Terp IM, Mortensen PB. Post-partum psychoses: clinical diagnoses and relative risk of admission after parturition. Br J Psychiatry. 1998; 172:521–526.
10.1192/bjp.172.6.521 CrossrefGoogle Scholar - 10.Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry. 2009; 66(2):189–195.
10.1001/archgenpsychiatry.2008.528 CrossrefGoogle Scholar - 11.Marengo E, Martino DJ, Igoa A, Unplanned pregnancies and reproductive health among women with bipolar disorder. J Affect Disord. 2015; 178:201–205.
10.1016/j.jad.2015.02.033 CrossrefGoogle Scholar - 12.Coverdale JH, Turbott SH, Roberts H. Family planning needs and STD risk behaviours of female psychiatric out-patients. Br J Psychiatry. 1997; 171:69–72.
10.1192/bjp.171.1.69 CrossrefGoogle Scholar - 13.Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994; 271:146–150.
10.1001/jama.1994.03510260078033 CrossrefGoogle Scholar - 14.Deligiannidis K, Byatt N, Freeman M. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014; 34(2):244–255.
10.1097/JCP.0000000000000087 CrossrefGoogle Scholar - 15.Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?Reprod Toxicol. 2009; 28(1):1–10.
10.1016/j.reprotox.2009.02.014 CrossrefGoogle Scholar - 16.Meador KJ, Baker GA, Browning N, NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012; 78(16):1207–1214
10.1212/WNL.0b013e318250d824 CrossrefGoogle Scholar - 17.Christensen J, Grønborg TK, Sørensen MJ, Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16):1696–1703.
10.1001/jama.2013.2270 CrossrefGoogle Scholar - 18.Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991; 324:674–677.
10.1056/NEJM199103073241006 CrossrefGoogle Scholar - 19.Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96:643–647.
10.1136/adc.2009.176990 CrossrefGoogle Scholar - 20.Hernández-Díaz S, Smith CR, Shen A, North American AED Pregnancy RegistryNorth American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78:1692–1699.
10.1212/WNL.0b013e3182574f39 CrossrefGoogle Scholar - 21.Holmes LB, Baldwin EJ, Smith CR, Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008; 70(22 Pt 2): 2152–2158.
10.1212/01.wnl.0000304343.45104.d6 CrossrefGoogle Scholar - 22.Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LTEUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?Neurology. 2008; 71(10):714–722.
10.1212/01.wnl.0000316194.98475.d8 CrossrefGoogle Scholar - 23.McKenna K, Koren G, Tetelbaum M, Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005; 66(4):444–449.
10.4088/JCP.v66n0406 CrossrefGoogle Scholar - 24.Cohen LS, Viguera AC, McInerney K, The National Pregnancy Registry for atypical antipsychotics: effects of fetal exposure on risk for major malformations.
Presented at: the Annual Meeting of the American Society of Clinical Psychopharmacology ;June 16, 2014 ;Hollywood, FL . Google Scholar - 25.Kulkarni J, Worsley R, Gilbert H, a prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014; 9(5):e94788
10.1371/journal.pone.0094788 CrossrefGoogle Scholar - 26.Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 2014; 5(2):100–109.
10.1177/2042098614522682 CrossrefGoogle Scholar - 27.Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med. 2009; 71(2):235–242.
10.1097/PSY.0b013e318190d7ca CrossrefGoogle Scholar - 28.Miller LJ, Ghadiali NY, Larusso EM, Bipolar disorder in women. Health Care Women Int. 2015; 36(4):475–498.
10.1080/07399332.2014.962138 CrossrefGoogle Scholar - 29.Wood W. What to tell your bipolar disorder patient who wants to breast-feed. Current Psychiatry. 2015; 14(4):30–33. Google Scholar
- 30.Sachs H. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013; 132(3):e796–e809.
10.1542/peds.2013-1985 CrossrefGoogle Scholar
